Vor Biopharma to Present at the Barclays Global Healthcare Conference
06 March 2021 - 7:00AM
Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering
engineered hematopoietic stem cell (eHSC) therapies combined with
targeted therapies for the treatment of cancer, today announced
that the Company will be participating in the Barclays Global
Healthcare Conference, which will take place virtually on March
9-11, 2021.
Robert Ang, MBBS, MBA, Vor’s President and Chief Executive
Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are
scheduled to present on Thursday, March 11, 2021, at 3:00 p.m. E.T.
A live webcast of the presentation can be accessed via the
Investors section of the Company's website at www.vorbio.com. An
archived replay of the webcast will be available on the Company's
website following the conference.
About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform
the lives of cancer patients by pioneering engineered hematopoietic
stem cell (eHSC) therapies to create next-generation,
treatment-resistant transplants that unlock the potential of
targeted therapies. By removing biologically redundant proteins
from eHSCs, we design these cells and their progeny to be
treatment-resistant to complementary targeted therapies, thereby
enabling these therapies to selectively destroy cancerous cells
while sparing healthy cells.
Contacts:
Investor: Constantine Davides, CFAWestwicke +1 339-970-2846
constantine.davides@westwicke.com
Media: Mary Carmichael Ten Bridge Communications +1 617-413-3543
mary@tenbridgecommunications.com
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart
From Jul 2023 to Jul 2024